Empagliflozin, sold most widely as Jardiance, is a SGLT2 inhibitor used for type 2 diabetes, heart failure and CKD. This guide covers how it works, what a standard course looks like, and how ShiningRX supplies it to trade buyers and consumers in the USA, UK and Australia.
Key takeaways
- Empagliflozin is a SGLT2 inhibitor indicated for type 2 diabetes, heart failure and CKD.
- Typical dosing: 10 mg once daily in the morning, increased to 25 mg.
- Onset is glucosuria within 24 hours, HbA1c effect over 12 weeks; effect lasts 24-hour dosing.
- Most reported side effects are genital mycotic infection and other mild, self-limiting reactions.
- Store below 30 °C.
Empagliflozin at a glance
| Attribute | Detail |
|---|---|
| Drug class | SGLT2 inhibitor |
| Common brand | Jardiance |
| Licensed use | type 2 diabetes, heart failure and CKD |
| Available strengths | 10 mg, 25 mg |
| Dosage form | film-coated tablet |
| Typical onset | glucosuria within 24 hours, HbA1c effect over 12 weeks |
| Duration / dosing interval | 24-hour dosing |
| Storage | below 30 °C |
How Empagliflozin works
As a SGLT2 inhibitor, Empagliflozin acts on the pathway that drives type 2 diabetes, heart failure and CKD. The pharmacological effect is dose-related, which is why prescribers begin at the lowest useful strength and adjust on response rather than starting at the maximum. In practice that means 10 mg once daily in the morning, increased to 25 mg
Starting a Empagliflozin course
- 1
Clinical assessment
Confirm the indication for type 2 diabetes, heart failure and CKD, review comorbidities and check the contraindication list before the first dose.
- 2
Initiate at the standard dose
10 mg once daily in the morning, increased to 25 mg
- 3
Review at the first checkpoint
Reassess once the expected onset window of glucosuria within 24 hours, HbA1c effect over 12 weeks has passed and document tolerability.
- 4
Titrate or switch
If response is partial and tolerance is good, step up within the licensed range; if tolerance is poor, consider Dapagliflozin.
Safety profile in brief
Commonly reported effects include genital mycotic infection, volume depletion, rare ketoacidosis. Empagliflozin should be avoided in type 1 diabetes and recurrent genital infections. Any severe, persistent or unexpected reaction warrants stopping the medicine and seeking clinical review.
